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Abstract
The purpose of this study was to determine the effect of 5 d of creatine (CRE) loading alone or in 
combination with caffeine anhydrous (CAF) or coffee (COF) on upper and lower body strength 
and sprint performance. Physically active males (n=54; Mean ± SD; Age = 20.1 ± 2.1 yrs; Weight 
= 78.8 ± 8.8 kg) completed baseline testing, consisting of one-repetition maximum (1RM) and 
repetitions to fatigue (RTF) with 80% 1RM for bench press (BP) and leg press (LP), followed by a 
repeated sprint test of five, 10 s sprints separated by 60 s rest on a cycle ergometer to determine 
peak power (PP) and total power (TP). At least 72 hr later, subjects were randomly assigned to 
supplement with CRE (5 g creatine monohydrate, 4 times*d−1; n=14), CRE+CAF (CRE + 300 
mg*d−1 of CAF; n=13), CRE+COF (CRE + 8.9 g COF, yielding 303 mg caffeine; n=13), or 
placebo (PLA; n=14) for 5 d. Serum creatinine (CRN) was measured prior to and following 
supplementation and on day six, participants repeated pre-testing procedures. Strength measures 
were improved in all groups (p<0.05), with no significant time × treatment interactions. No 
significant interaction or main effects were observed for PP. For TP, a time × sprint interaction was 
observed (p<0.05), with no significant interactions between treatment groups. A time × treatment 
interaction was observed for serum CRN values (p<0.05) that showed increases in all groups 
except PLA. Four subjects reported mild gastrointestinal discomfort with CRE+CAF, with no side 
effects reported in other groups. These findings suggest that neither CRE alone, nor in 
combination with CAF or COF, significantly affected performance compared to PLA.
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Introduction
Creatine (CRE) and caffeine (CAF) supplements are commonly used by athletes to improve 
performance. Surveys conducted in 2004 and 2005 revealed that 37% of Division I 
collegiate athletes had used CRE supplements (13), and 89% of triathletes intended to use 
CAF either before or during their upcoming race (10). Creatine supplementation has been 
shown to increase muscle phosphocreatine (PCr) storage (18), which increases adenosine 
triphosphate (ATP) availability and improves exercise performance (6). During intense 
exercise there is an elevated demand for ATP which allows for sustained crossbridge cycling 
and force output. The rapid provision of ATP is facilitated by stored PCr, which 
phosphorylates adenosine diphosphate in the creatine kinase reaction; creatine is cycled 
through this reaction from phosphocreatine to CRE. To date, hundreds of studies have 
investigated the effects of CRE supplementation on exercise performance, with the majority 
of studies demonstrating an ergogenic effect on strength and sprint performance lasting less 
than 30 seconds (5, 21, 23, 30, 40, 41, 43).
While CRE is primarily effective for enhancing short-term bouts of high intensity and 
intermittent exercise (5, 30, 41), CAF has been shown to have ergogenic effects for both 
anaerobic (7, 32, 42) and endurance exercise performance (8, 20). While the primary 
ergogenic mechanism of CAF is antagonism of adenosine receptors, it may affect 
performance by a number of both central and peripheral mechanisms (1, 11, 14, 22, 27). In 
previous literature, CAF doses ranging from 3-6 mg*kg−1 of body mass have been 
consistently shown to improve endurance performance (8, 14, 20). Evidence also suggests 
that CAF improves strength (3, 44) and sprint (32, 42, 44) performance, particularly in 
trained subjects (7).
Creatine and CAF do not display pharmacokinetic interactions when ingested together (37), 
and are thought to improve performance via independent mechanisms, which has prompted 
interest in the potential for combined supplementation. Previous studies have reported 
performance improvements from CRE mixed into caffeinated tea or coffee (COF) (4, 9), and 
a number of multi-ingredient supplements containing CRE+CAF, among other ingredients, 
have been shown to improve outcomes for strength, power, and body composition (15, 28, 
33). Research has also indicated that acute CAF supplementation (a single dose, consumed 
60 min prior to an exercise bout) after CRE loading may improve performance more than 
CRE loading alone (24, 25). However, the scarce research directly investigating combined 
supplementation has indicated that 3-4 d of CAF supplementation (consumed for multiple 
consecutive days during CRE loading) may blunt the ergogenic effect of CRE loading (17, 
19, 38). This apparent incompatibility could potentially be explained by CRE and CAF 
imposing opposite effects on muscle relaxation time (19), or by gastrointestinal distress 
caused by concurrent ingestion of both ingredients (17, 31). It is currently unclear if these 
discrepant findings may relate to differences in the dose or source of caffeine consumed. 
Further research is warranted to determine if 5 d of daily COF or CAF consumption blunt 
the ergogenic effect of CRE loading, as both CRE and CAF are commonly used by 
recreational and competitive athletes prior to training and competition. Results of such 
research may assist athletes and practitioners in maximizing the potential benefits of both 
CRE loading and CAF supplementation. Therefore, the purpose of the current study was to 
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determine the effect of 5 d of CRE loading alone or in combination with CAF or COF on 
upper and lower body strength and sprint performance in physically active males.
Methods
EXPERIMENTAL APPROACH TO THE PROBLEM
The current randomized, partially blinded study consisted of two laboratory visits, with a 5 d 
supplementation period preceding the second visit. Baseline testing included serum 
creatinine levels, one-rep maximum (1RM) and repetitions to fatigue (RTF) for leg press 
(LP) and bench press (BP), and a repeated sprint protocol to determine peak power (PP) and 
total work (TW) output. At least 72 hr after baseline testing, participants began 
supplementation with either CRE monohydrate (CRE; 20 g*d−1; n=14), CRE and caffeine 
anhydrous (CRE+CAF; 20 g*d−1 CRE and 300 mg*d−1 of CAF; n=13), CRE and COF 
(CRE+COF; 20 g*d−1 creatine and 8.9 g*d−1 of instant coffee yielding 303 mg of CAF; 
n=13), or placebo (PLA; n=14). Participants supplemented for 5 d and returned to the 
laboratory on day six for serum creatinine analysis and exercise testing.
SUBJECTS
Fifty-four males aged 18-35 yrs (Mean ± SD; Age = 20.1 ± 2.1 yrs; Height = 177.3 ± 5.6 
cm; Body mass = 78.8 ± 8.8 kg) who had been resistance training for ≥30 min*d−1, 3 
d*wk−1 for at least 3 mo completed the current study. Fifty-six participants enrolled in the 
study; two dropped out for personal reasons after baseline testing but prior to the onset of 
supplementation. Exclusion criteria included supplementation with CRE or beta-alanine in 
the 3 mo prior to the study, habitual CAF intake of over 800 mg*d−1, or a history of adverse 
reactions to caffeine. Participants were also excluded if they were not willing to abstain from 
substances known to significantly influence the cytochrome P450 1A2 isozyme that 
metabolizes caffeine (i.e., tobacco products, antidepressant drugs) for the duration of the 
study. Average habitual CAF intake for participants was 32.9 ± 59.6 mg*d−1 (range = 0 – 
214 mg*d−1). Participants were instructed to abstain from CAF intake within 48 hr of 
baseline testing, and to avoid strenuous exercise within 24 hr of all testing sessions. Aside 
from these restrictions, participants were encouraged to maintain their normal training and 
dietary habits, and to replicate similar food intake before visits to the laboratory. Each 
participant completed a 3 d dietary log at baseline that was analyzed using The Food 
Processor software (ESHA Research, Salem, OR, USA) to evaluate habitual dietary intakes. 
Laboratory visits occurred at a similar time of day (± 2 hr). All methodology was approved 
by the University's Biomedical Institutional Review Board, and all participants signed an 
informed consent prior to participation.
PROCEDURES
Serum Creatinine—Prior to exercise at each laboratory visit, a 3.5 mL sample of blood 
was obtained from a vein in the antecubital region of the arm using a BD Vacutainer Serum 
Separator Tube (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Blood 
samples were immediately stored in a refrigerator, then transported to an independent 
laboratory (Core Laboratory, McLendon Clinical Labs, UNC Hospitals, Chapel Hill, NC) for 
serum creatinine analysis no more than 12 hr after sample collection.
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One Repetition Maximum & Repetitions to Fatigue—One-repetition maximum for 
LP and BP were determined using free weights (York Barbell Co., York, PA, USA) and a 
spotter. Before testing, participants were allowed time for a brief warm up and technique 
familiarization. The first warm up set consisted of 8-10 repetitions performed with a load 
estimated to be 50% of 1RM. After 1-2 min of rest, participants performed a second warm 
up set consisting of 80% of the anticipated 1RM, lifted for 4-6 repetitions. Participants were 
allowed 2 min of rest, after which participants completed their first 1RM attempt. For all 
subsequent sets, the load was adjusted and a single repetition was performed until the 1RM 
was identified, with 2-3 min of rest provided between attempts.
Following the final 1RM attempt for a given lift, participants rested for three min, after 
which the RTF test was completed. This test consisted of lifting 80% of the 1RM load for as 
many repetitions as possible, until failure was reached. Testing was supervised by trained 
laboratory personnel, and failure was defined as the point at which a full repetition could no 
longer be completed with appropriate technique. Verbal encouragement was provided for all 
strength testing. For the second laboratory visit, participants used the same load (80% of 
baseline 1RM) for the RTF test, regardless of any changes in 1RM. In all testing sessions, 
leg press 1RM and RTF testing preceded the bench press. Reliability calculations from our 
laboratory have indicated an intraclass correlation coefficient (ICC2,1) of 0.97 and 0.99 for 
LP and BP 1RM, respectively, in resistance trained males (n=11) with at least 48 hr between 
tests. The standard error of measurement (SEM) for LP and BP 1RM are 7.4 kg and 1.9 kg, 
respectively.
Repeated Sprint Protocol—Ten min after the conclusion of strength testing, participants 
completed a repeated sprint test consisting of five, 10 s sprints on a Monark friction-braked 
cycle ergometer (Ergomedic 894 E; Monark, Stockholm, Sweden). Participants completed a 
self-paced, 5 min warm up with a standardized load of 0.5 kg. After the warm up, 
participants completed the sprint protocol adapted from Wiroth et al. (43), completing five 
maximal sprints lasting 10 s each, with a load of 95 g*kg−1 of body mass applied to the 
weight basket. Each sprint was followed by a passive rest period of 60 s. Participants 
remained in a seated position for the duration of each sprint, and verbal encouragement was 
provided by lab personnel. For each sprint, PP and TW were evaluated using the default 
software (Monark ATS Software; Monark, Stockholm, Sweden). For this sprint protocol, 
reliability calculations from our laboratory have indicated an ICC of 0.96 and SEM of 19.7 
watts for average PP in resistance trained males (n=12) with at least 48 hr between tests.
Supplementation—Participants were randomly assigned to a treatment group for five 
continuous days of supplementation, using a computer generated allocation sequence 
(Random Allocation Software, Isfahan, Iran). One group (CRE; n=14) consumed a loading 
dose (20 g*d−1, split between 4 servings) of creatine monohydrate (Micronized Creatine 
Powder; Optimum Nutrition, Aurora, IL, USA) mixed with noncaloric flavoring (Crystal 
Light; Kraft Foods, Northfield, IL, USA). A second group (CRE+CAF; n=13) followed the 
same creatine loading protocol, but with 300 mg of caffeine anhydrous (CAF; Smart 
Powders, Graham, NC, USA) added to the first dose of each day. A third group (CRE+COF; 
n=13) followed the creatine loading protocol, but mixed each day's first dose of creatine into 
Trexler et al. Page 4
J Strength Cond Res. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
a caffeine-matched serving (8.9 g) of instant coffee (COF; Nescafé House Blend; Nestle, 
Vevey, Switzerland). The final group (PLA; n=14) consumed a flavored, noncaloric placebo 
beverage (3.8 g Crystal Light), ingested four times daily. Participants were instructed to 
consume their respective supplement at regular intervals throughout the day. It was 
suggested to mix the supplement with 300 mL of water, but participants were permitted to 
deviate from this suggestion, if necessary, to satisfy individual taste preferences. All 
participants weighed between 60-100 kg, to ensure that 300 mg CAF doses were between 
3-5 mg*kg−1 of bodyweight. The current study may be considered partially blinded, as COF 
has a distinct taste. However, laboratory personnel were blinded to the groups, and 
participants did not know if the coffee-flavored beverage contained caffeine. Previous 
research has used a similar instant coffee product and verified a caffeine concentration of 3.4 
g caffeine/100 g of instant coffee (20). As such, caffeine content was approximately matched 
between CRE+CAF and CRE+COF treatment arms (300 mg and 303 mg, respectively), 
which equates to an average caffeine dose of approximately 3.8 mg*kg−1 in the current 
sample.
Throughout supplementation, subjects were instructed to maintain their normal diet and 
exercise habits, but to abstain from any extraneous CAF consumption. To ensure 
compliance, participants were required to document their supplement intake in a written log. 
Analysis of supplement logs indicated compliance rates of 99% or greater in all groups. 
After 5 d of supplementation, participants reported for the second exercise testing session on 
day six. To avoid an acute ergogenic effect of COF or CAF intake, there was no 
supplementation on day six, regardless of treatment group.
STATISTICAL ANALYSES
Data are expressed as mean ± standard deviation with the exception of Figure 1 and Figure 
2, which depict 95% confidence intervals. A series of one-way ANOVAs were used to 
evaluate baseline differences between groups for dietary intakes, strength outcomes, sprint 
outcomes, and serum creatinine values. Strength changes were evaluated using a series of 
two-way (2 × 4; time × treatment) repeated measures ANOVAs. Peak power and TW 
achieved during each sprint, along with average PP and TW, were compared using mixed 
factorial ANOVAs (2 × 5 × 4; time × sprint × treatment) with Bonferroni post hoc 
comparisons. Serum creatinine and body weight values were compared using mixed factorial 
ANOVAs (2 × 4; time × treatment). In the event of a significant interaction, Bonferroni post 
hoc comparisons were completed using specialized syntax to identify the source of the 
interaction.
For serum creatinine values and all performance outcomes, 95% confidence intervals (CI) 
were calculated for change scores from baseline to post-testing (mean ± 1.96 × SEM). A 
change was considered significantly significant (p≤0.05) if zero did not fall within the 95% 
confidence interval. Microsoft Excel (Version 2011, Microsoft Corporation; The Microsoft 
Network, LLC, Richmond, WA, USA) was used to calculate and plot 95% confidence 
intervals. All other statistical analyses were performed using SPSS software, (Version 20.0; 
IBM, Armonk, NY, USA), with the level of significance set a priori at α ≤ 0.05.
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Results
Descriptive characteristics and dietary intakes are listed by group in Table 1. There were no 
significant differences (p>0.05) between groups for anthropometric measures, macronutrient 
intakes, or CAF intake at baseline.
Strength outcomes
For all strength outcomes, there were no significant interaction effects or main effects for 
treatment (all p>0.05). However, significant main effects for time were observed for BP 
1RM (p<0.05; mean Δ= 2.5% increase; Table 2), BP RTF (p<0.05; mean Δ= 0.9 repetition 
increase), LP 1RM (p<0.05; mean Δ= 6.4% increase; Table 2), and LP RTF (p<0.05; mean 
Δ= 4.2 repetition increase).
Analysis of 95% confidence intervals for change scores indicated that all groups 
significantly improved BP and LP 1RM from baseline to post-testing (Table 2). For LP RTF, 
95% CIs demonstrated significant increases in repetitions for PLA [CI: 2.9, 7.0 repetitions], 
CRE+COF [1.5, 5.6], CRE+CAF [2.0, 6.8], and CRE [1.1, 6.8]. For BP RTF, 95% CIs 
indicated significant increases in repetitions for PLA [CI: 0.6, 2.4 repetitions], CRE+CAF 
[0.2, 1.2], and CRE [0.4, 1.4], but not for CRE+COF [−0.6, 1.1].
Sprint outcomes
Peak power and TW for each sprint are presented in Table 3. For PP, the time × sprint × 
treatment interaction was not significant (p>0.05). Similarly, there were no significant time 
× sprint (p=0.13), sprint × treatment (p>0.05), or time × treatment (p>0.05) interactions. A 
significant main effect was observed for sprint (p<0.05), but not for time or treatment (both 
p>0.05). Post hoc comparisons of marginal means revealed that PP dropped significantly 
between all five sprints (all p<0.05).
For TW, the time × sprint × treatment interaction was not significant (p>0.05), but a 
significant time × sprint interaction was observed (p<0.05). There were no significant 
differences between pre- and post-test values for TW for any sprint; post hoc comparisons 
showed significant reductions in TW between all five sprints for pre-testing (p<0.05), while 
the TW drop between sprints 4 and 5 were not significant in post-testing (p>0.05). Sprint × 
treatment and time × treatment interactions were not significant (both p>0.05). A significant 
main effect was observed for sprint (p<0.05), but not for time or treatment (both p>0.05).
Analysis of 95% confidence intervals for change scores revealed no statistically significant 
changes in PP or TW for any sprint, or in average PP or TW, in any treatment group (Table 
3). Confidence intervals for changes in average TW are presented in Figure 1.
Serum creatinine values
A significant time × treatment interaction was observed for serum creatinine (CRN) values 
(p<0.05). Bonferroni post hoc comparisons revealed a significant difference between PLA 
and CRE+COF after supplementation (p<0.05), with no other significant differences 
between groups. Post hoc comparisons identified significant increases from pre- to post- 
testing in CRE+COF and CRE+CAF (p<0.05), but not in CRE (p=0.09) or PLA (p>0.10). 
Trexler et al. Page 6
J Strength Cond Res. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Analysis of 95% confidence intervals for change scores revealed a significant increase in 
serum CRN values for CRE [CI: 0.01, 0.15 mg/dL], CRE+COF [0.05, 0.35], and CRE+CAF 
[0.06, 0.25], but not for PLA (Figure 2).
Reported side effects
Four participants (30.8%) given CRE+CAF reported mild gastrointestinal (GI) disturbance, 
which was not reported in any other group. For changes in body weight, there was no 
significant time × treatment interaction, with no main effects for time or treatment (all 
p>0.05). Weight was slightly reduced in PLA (−0.2 ± 1.0 kg) and CRE+COF (−0.2 ± 1.2 
kg), with small increases observed in CRE+CAF (0.5 ± 0.7 kg) and CRE (0.1 ± 0.7 kg).
Discussion
Previous research has suggested that 3-4 d of CAF intake blunts the ergogenic effect of CRE 
loading (17, 19, 38). In contrast, studies have demonstrated the efficacy of CRE 
supplementation when mixed into caffeinated tea or COF (4, 9). Because many pre-workout 
supplement formulations include both CRE and CAF (15, 28, 33), further research on the 
potential interaction is needed. While previous studies on CRE+CAF supplementation have 
employed unique exercise tests consisting of electrical stimulation (19) or isokinetic knee 
extension (17, 38), the current study used dynamic exercise tests relating more closely to the 
training of many resistance trained individuals. Strength outcomes were improved in all 
groups, except for a non-significant improvement in BP RTF for CRE+COF. For sprint 
outcomes, no group interactions were observed for PP or TW. Although not statistically 
significant, average TW was reduced in PLA, but not in CRE+CAF, CRE+COF, or CRE 
(Figure 1). Confidence intervals indicated that serum creatinine values were elevated in all 
treatment groups, except PLA.
In the current study, upper and lower body strength measurements improved in all treatment 
groups, with the exception of BP RTF for CRE+COF, which did not change. A meta-
analysis published in 2003 (5), including interventions of varying duration, indicated that 
CRE supplementation led to significant improvements in 1RM and RTF. Creatine loading 
interventions (5-7 d) have demonstrated increases in muscle PCr storage (16), while changes 
in strength have been mixed. Although CRE loading has been shown to increase indices of 
maximal strength (21, 40) and RTF (21, 41), Zuniga et al. (45) found no effect of CRE 
loading on 1RM for leg extension or BP in untrained men. Izquierdo et al. (21) documented 
improvements in half-squat 1RM, half-squat RTF, and BP RTF in trained handball players, 
while BP 1RM did not improve. Volek et al. (40) reported improvements in BP 1RM with 
one week of CRE loading in resistance trained males, but no change in squat 1RM or BP 
RTF. In the current study, CRE did not improve strength outcomes more than PLA, with or 
without the addition of COF or CAF. Single-rep strength performance is not likely limited 
by the phosphagen energy system, which may explain the results observed for 1RM. For 
RTF, null findings could possibly be explained by the presence of non-responders in the 
sample, as up to 30% of individuals may not see performance benefits from CRE (16, 35). It 
is also possible that day to day variability in performance may be too large in moderately 
trained subjects, or subjects performing testing that does not mimic their normal training 
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habits, to detect the modest benefits of CRE supplementation. As such, more sensitive 
measures of strength (i.e. maximal voluntary contraction) may be needed to consistently 
detect strength improvements from short-term CRE loading, and future studies should 
employ exercise tests that closely resemble the regular training of a highly trained sample. 
Previous research has also shown that longer CRE supplementation protocols lasting 10-12 
weeks, with concurrent resistance training, have yielded greater improvements in strength 
outcomes compared to short-term loading (39, 40), suggesting that a longer duration of 
supplementation may be necessary to detect an ergogenic effect in moderately trained 
subjects.
For sprint outcomes, no significant changes in PP or TW were observed for any group. It 
was hypothesized that CRE would improve sprint performance, as CRE is thought to be 
particularly effective for repetitive high-intensity bouts lasting ≤30 seconds (5). A number of 
previous studies have shown CRE supplementation to improve performance on both single 
(34) and repeated (4, 9, 30, 34, 36) sprint tests, with samples ranging from recreationally 
active (30) to elite-level athletes (36). However, McKenna et al. (26) demonstrated that CRE 
did not improve performance on a repeated sprint test consisting of five ten-second sprints 
with variable rest periods in recreationally active subjects. Finn et al. (12) also reported no 
benefit of CRE on a protocol consisting of four 20-second sprints with 20 seconds of rest 
between sprints in trained triathletes. Using a sprint protocol similar to that of the current 
study, Wiroth et al. (43) found CRE to improve performance in both young and old 
sedentary participants, but not in well-trained participants. It is not clear if the lack of 
improvement in the current study is a result of the sprint protocol employed, or 
characteristics of the sample. Despite the non-significant statistical results, it does appear 
that average TW declined in PLA, but was maintained in all groups consuming CRE (Figure 
1). This may have practical significance, as it suggests a modest benefit of CRE loading for 
individuals who are reliant on repetitive, intermittent bursts of high-intensity activity. 
Similarly to strength outcomes, the inclusion of CAF or COF with CRE did not appear to 
negatively affect sprint performance.
While no pharmacokinetic interaction has been observed between CRE and CAF (37), 
Vandenberghe et al. (38) demonstrated that CAF blunted the ergogenic effect of CRE 
loading. Subsequent research suggested that opposing effects on muscle relaxation time may 
explain this interaction (19). Results of Vandenberghe et al. (38) may have been influenced 
by an insufficient washout period (three weeks), or CAF withdrawal, as the final CAF dose 
was ingested at least 20 hr before post-testing. In a published abstract, Harris et al. (17) 
sought to replicate the findings of Vandenberghe et al. (38), but employed a six week 
washout period and included post-test sessions both two and 24 hr after CAF cessation. 
While CAF appeared to blunt the ergogenic effect of CRE, the authors (17) suggested that 
this effect was explained by GI discomfort with CRE+CAF, which was reported in four out 
of ten subjects completing the study. Gastrointestinal discomfort was also noted in another 
recent study involving CRE+CAF supplementation (31), in which three out of seven subjects 
reported symptoms. In agreement with past studies, GI discomfort was reported in four of 
thirteen participants in the CRE+CAF group in the current study. While mild GI distress has 
been reported anecdotally with CRE supplementation (29), it was not reported by any 
participants in PLA, CRE, or CRE+COF. Future studies should seek to determine if 
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individuals engaged in strength or sprint training can successfully combine CRE and CAF 
by employing supplement timing strategies to mitigate GI distress and CAF withdrawal 
before exercise.
In agreement with previous research (29), serum CRN values in the present study were 
significantly elevated in all groups supplementing with CRE (Figure 2). High serum CRN is 
an indirect indicator of impaired kidney function, but values can be influenced by a number 
of factors including age, sex, lean mass, diet, physical activity, and creatine supplementation 
(2, 29). Changes in serum CRN were greater in CRE+COF and CRE+CAF compared to 
CRE, but differences were not statistically significant. Supplement logs indicated a 
compliance rate of ≥99%, as supported by changes in serum CRN. In individuals 
supplementing with CRE, high serum CRN levels should be interpreted with caution, as 
increased creatine breakdown may increase serum CRN in the absence of impaired kidney 
function (29). Creatine is osmotically active, and CRE loading generally results in a weight 
gain of 1-2 kg in men due to water retention (29). Despite excellent compliance, the current 
study did not find a significant time × treatment interaction for body weight, with no group 
increasing by more than 0.5 kg. It is unknown if this lack of weight gain may relate to the 
high protein intake reported by participants, which is generally associated with greater 
dietary creatine intake, inadequate hydration, or other factors. Elevated serum CRN and lack 
of weight gain could potentially be indicative of poor muscle CRE uptake, although these 
values are often variable and influenced by a number of factors. While Syrotuik et al. (35) 
found that creatine non- and quasi-responders gained less weight and had greater increases 
in urinary CRN compared to responders after CRE loading, differences were non-significant 
and varied between individuals. As such, these values may not be valid indicators for 
identifying CRE non-responders.
Limitations of the current study must be noted. While the 5 d CRE loading protocol has been 
shown to increase muscle creatine stores (16), more pronounced performance effects would 
likely be observed with a longer supplementation period accompanied by progressive 
resistance training. Despite the recruitment of physically active participants with weight 
training experience, strength improvements in the PLA group may indicate a learning effect 
or placebo effect for 1RM and RTF, but not for sprint outcomes. Although 1RM and RTF are 
highly applicable to the training of athletes, more sensitive indices of strength may be 
favorable for future studies on short-term creatine loading. It is also important to note that 
subjects in the current study were physically active, but not competitive athletes. Finally, the 
current study did not directly measure muscle creatine content, and therefore cannot rule out 
the presence of nonresponders in the sample. Future research should investigate the effects 
of COF and CAF with a longer period of CRE supplementation combined with progressive 
resistance training, and seek to determine if supplement timing and dosing strategies can be 
employed to obtain the ergogenic benefits associated with CRE and CAF without 
experiencing GI discomfort.
Practical Applications
Creatine loading did not improve strength or sprint outcomes to a greater extent than 
placebo, and the addition of 300 mg of CAF in the form of anhydrous powder or instant 
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COF had no statistically significant effects on performance in physically active men. While 
differences were not statistically significant, reductions in TW output were attenuated to a 
similar extent by CRE, CRE+CAF, and CRE+COF, compared to PLA. Results support 
previous research indicating that GI discomfort is observed with combined CRE+CAF 
supplementation, while this was not observed with CRE+COF. In physically active men, 
longer periods of CRE supplementation combined with progressive training may be required 
to see significant improvements in the outcomes measured, as groups consuming CRE did 
not outperform PLA to a significant degree. Athletes and resistance trained individuals 
supplementing with CRE may be advised to consider the source, dose, and timing of any 
CAF consumed to avoid GI discomfort.
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Figure 1. 
Mean (± 1.96 × SEM) and individual changes in average total work (TW; joules) after 
supplementation.
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Figure 2. 
Mean (± 1.96 × SEM) and individual changes in serum creatinine (mg/dL) after 
supplementation. *Significant change from baseline value, as determined by 95% 
confidence intervals (p≤0.05); § significantly greater than placebo (p≤0.05)
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Table 1
Baseline characteristics and habitual dietary intakes by group.
PLA (n=14) CRE+COF (n=13) CRE+CAF (n=13) CRE (n=14)
Age (yrs) 19.9 ± 2.0 20.0 ± 1.3 20.2 ± 2.7 20.3 ± 2.3
Height (cm) 175.2 ± 7.0 177.6 ± 5.0 177.7 ± 5.3 178.7 ± 5.0
Weight (kg) 77.7 ± 9.2 77.9 ± 7.6 80.8 ± 10.6 78.7 ± 8.4
Calories (kcal) 2891.9 ± 941.9 2613.1 ± 680.1 2578.2 ± 378.7 2518.9 ± 372.7
CHO (g/day) 304.2 ± 103.4 307.3 ± 112.5 266.1 ± 74.4 288.7 ± 100.0
FAT (g/day) 126.3 ± 50.6 102.5 ± 28.0 106.2 ± 26.6 93.9 ± 23.5
PRO (g/day) 136.4 ± 43.8 124.2 ± 30.4 138.6 ± 35.2 131.9 ± 24.2
CAF (mg/day) 18.4 ± 57.5 12.1 ± 29.1 54.6 ± 76.0 46.4 ± 60.9
Values are mean ± SD
CHO = carbohydrate intake, PRO = protein intake, CAF = habitual caffeine intake
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Table 2
Effects of supplementation on leg press and bench press 1RM (kg) for placebo (PLA), creatine + coffee (CRE 
+ COF), creatine + caffeine (CRE + CAF), or creatine alone (CRE). Values are mean ± SD
LP 1RM (kg) BP 1RM (kg)
Treatment Pre Post Pre Post
PLA 288.0 ± 73.2 308.9 ± 71.6* 89.6 ± 12.8 92.0 ± 13.3*
CRE+COF 289.0 ± 52.5 305.6 ± 52.0* 88.1 ± 15.6 90.2 ± 14.9*
CRE+CAF 299.6 ± 93.0 313.8 ± 97.0* 97.2 ± 20.9 99.3 ± 20.8*
CRE 288.0 ± 79.1 309.4 ± 76.0* 92.4 ± 21.7 95.0 ± 22.1*
*Significant change from baseline, as determined by 95% confidence intervals
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